While mesothelin is robustly expressed in pancreatic cancers, one additional theory is that targeting the glycosylated portion is susceptible to cleavage, which could offer a mechanism that limits CAR T cell efficacy. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.